Problem · Owners
We send hundreds of cold emails and nobody replies.
You bought a tool, bought a list, wrote a sequence, and sent 2,000 emails. Nine people replied and four of them said unsubscribe. The instinct is to rewrite the copy. The copy is rarely the problem. The list is, and in a technical market the first sentence is, because the buyer decides in that sentence whether you understand their work.
How people search thiscold email no replies · cold email reply rate too low · why is nobody responding to my cold emails · cold outreach not working B2B · cold email reply rate benchmark 2026
Kinetic at $10,000 a month includes one outbound seat: list building from primary data, sequences written by the team that wrote your site, coordinated email, phone, and LinkedIn, and a monthly meeting number in writing. Catalyst can add the seat for $4,500. Pricing is published.
What normal looks like
SciLeads' 2026 benchmark of science sales teams puts average cold email open rate at 10.7 percent and average reply rate at 4.2 percent, with wide variation. The teams above 11 percent replies used phone, LinkedIn, and video alongside email far more often than the rest. Only 29 percent of respondents used the phone at all. If you are under 1 percent on email alone, you are not unlucky. You are running one channel into a list that was not built for you.
The list decides it
A purchased list is the same list your competitors bought, filtered by job title, with 20 to 30 percent of contacts stale by the time you send. A built list starts from primary data: public datasets, publications, funding events, registries, technographics. For one healthcare revenue client we built the entire prospect universe from federal public use files before a single email went out. Every contact was a real buyer of the exact thing, and the first sentence could name why.
In a life science market, the buyer of record for most purchases under $50,000 is the lab manager or core director, not the principal investigator. Sequences to PIs referencing nothing get deleted. Sequences to lab managers referencing the lab's last paper get read.
The first sentence and the website
A PI decides whether to reply in the first sentence, and it has to name the model, the assay, or the phenotype correctly. A practice administrator decides on whether you understand referral patterns and payer mix. Generic openers fail with these buyers at any volume. Then the prospect who is interested looks you up. If the site does not confirm what the email claimed, the reply never comes. Our sequences are written by the same team that wrote the site, so the diligence confirms the outreach.
Multichannel, confirmed, measured on held meetings
Email, phone, and LinkedIn in one cadence over two to three weeks, with eighteen documented plays covering triggers from a new executive hire to a funding event. Every booked meeting gets a confirmation sequence, because no show rates above 30 percent are common when nobody runs one. Report on meetings held and pipeline created, not opens. Opens are a vanity metric with a tracking pixel.
Questions on this problem
No tool fixes a bad list. Deliverability matters, but the accounts we take over almost always have a list and messaging problem first.
Fewer than you think. A serious program reaches a few hundred right accounts deeply across three channels rather than ten thousand badly on one.
Automation runs research, list building, and sequencing. The conversations that qualify and book are run by people, because your buyers can tell.
George Stoff, Founder and Lead Engineer
Thirty years building software, brands, and demand. On every account.